Insider Trading Alert - DO, IBKR, COV, WLP And ACT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 16, 2013, 116 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $164.25 to $16,145,446.22.

Highlighted Stocks Traded by Insiders:

Diamond Offshore Drilling (DO) - FREE Research Report

Gaffney Paul G who is Director at Diamond Offshore Drilling bought 1,000 shares at $56.18 on Dec. 16, 2013. Following this transaction, the Director owned 2,000 shares meaning that the stake was reduced by 100% with the 1,000-share transaction.

The shares most recently traded at $55.73, down $0.45, or 0.8% since the insider transaction.

The average volume for Diamond Offshore Drilling has been 1.2 million shares per day over the past 30 days. Diamond Offshore Drilling has a market cap of $7.8 billion and is part of the basic materials sector and energy industry. Shares are down 17.32% year-to-date as of the close of trading on Monday.

Diamond Offshore Drilling, Inc. operates as an offshore oil and gas drilling contractor worldwide. It provides offshore drilling services in both the floater market, such as ultra-deepwater, deepwater, and mid-water; and in the non-floater and jack-up markets. The stock currently has a dividend yield of 0.89%. The company has a P/E ratio of 12.8. Currently there are 4 analysts that rate Diamond Offshore Drilling a buy, 5 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DO - FREE

TheStreet Quant Ratings rates Diamond Offshore Drilling as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Diamond Offshore Drilling Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Nemser Earl H who is Vice Chairman at Interactive Brokers Group sold 13,376 shares at $24.45 on Dec. 16, 2013. Following this transaction, the Vice Chairman owned 330,047 shares meaning that the stake was reduced by 3.89% with the 13,376-share transaction.

Brody Paul Jonathan who is Chief Financial Officer at Interactive Brokers Group sold 7,437 shares at $24.45 on Dec. 16, 2013. Following this transaction, the Chief Financial Officer owned 183,498 shares meaning that the stake was reduced by 3.9% with the 7,437-share transaction.

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 2,000 shares at $24.23 on Dec. 16, 2013. Following this transaction, the SVP Software Development owned 733,604 shares meaning that the stake was reduced by 0.27% with the 2,000-share transaction.

The shares most recently traded at $24.17, down $0.06, or 0.25% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,000
  • 12-Week # shares sold: 54,000
  • 24-Week # shares sold: 111,000

The average volume for Interactive Brokers Group has been 498,500 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.2 billion and is part of the financial sector and financial services industry. Shares are up 79.02% year-to-date as of the close of trading on Monday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.63%. The company has a P/E ratio of 28.5. Currently there are 2 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien (COV) - FREE Research Report

King Brian Douglas who is Vice President at Covidien sold 5,000 shares at $66.50 on Dec. 16, 2013. Following this transaction, the Vice President owned 37,028 shares meaning that the stake was reduced by 11.9% with the 5,000-share transaction.

The shares most recently traded at $65.78, down $0.72, or 1.09% since the insider transaction. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares sold: 39,397
  • 12-Week # shares sold: 113,145
  • 24-Week # shares sold: 129,736

The average volume for Covidien has been 2.1 million shares per day over the past 30 days. Covidien has a market cap of $29.8 billion and is part of the health care sector and health services industry. Shares are up 13.98% year-to-date as of the close of trading on Monday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.94%. The company has a P/E ratio of 19.4. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

WellPoint (WLP) - FREE Research Report

Cannon John who is EVP, GC & Chief PAO at WellPoint sold 9,558 shares at $87.73 on Dec. 16, 2013. Following this transaction, the EVP, GC & Chief PAO owned 99,331 shares meaning that the stake was reduced by 8.78% with the 9,558-share transaction.

The shares most recently traded at $87.02, down $0.71, or 0.82% since the insider transaction. Historical insider transactions for WellPoint go as follows:

  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 55,056

The average volume for WellPoint has been 2.3 million shares per day over the past 30 days. WellPoint has a market cap of $25.9 billion and is part of the health care sector and health services industry. Shares are up 43.94% year-to-date as of the close of trading on Monday.

WellPoint, Inc., a health benefits company, through its subsidiaries, offers network-based managed care plans to large and small employer, individual, Medicaid, and senior markets in the United States. The company operates through three segments: Commercial, Consumer, and Other. The stock currently has a dividend yield of 1.71%. The company has a P/E ratio of 9.5. Currently there are 6 analysts that rate WellPoint a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WLP - FREE

TheStreet Quant Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full WellPoint Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis (ACT) - FREE Research Report

Bodine Chris W who is Director at Actavis sold 3,000 shares at $159.67 on Dec. 16, 2013. Following this transaction, the Director owned 11,629 shares meaning that the stake was reduced by 20.51% with the 3,000-share transaction.

The shares most recently traded at $158.27, down $1.40, or 0.89% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.5 million shares per day over the past 30 days. Actavis has a market cap of $27.8 billion and is part of the health care sector and drugs industry. Shares are unchanged year-to-date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

TheStreet Quant Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment